Document Detail


Nadolol versus diltiazem and combination for preventing exercise-induced ischemia in severe angina pectoris.
MedLine Citation:
PMID:  3414514     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Combination beta-blocker and calcium antagonist therapy has been shown to be superior to monotherapy with either class of drugs in the treatment of patients with severe angina pectoris. Some combinations of these agents have resulted in an increased frequency of adverse effects. Although nadolol and diltiazem have low incidences of side effects as monotherapy, little is known about their combination. Thus, 18 patients with angina pectoris despite medical therapy were randomly assigned to 3-week periods of nadolol (160 mg/day), diltiazem (240 mg/day) or their combination. At the end of each treatment period, treadmill exercise testing and rest and peak bicycle exercise 2-dimensional echocardiography were performed. The heart rate-systolic blood pressure product was decreased most at peak treadmill exercise with the combination therapy versus monotherapy with either nadolol or diltiazem (12 vs 14 vs 22 x 10(3), respectively, p less than 0.05). Exercise duration did not differ with any of the 3 regimens, but the number of patients without angina during exercise was lowest with the combination therapy versus nadolol or diltiazem alone (5, 10 and 11, respectively, p less than 0.05); similar results were noted with the number of patients developing 1-mm ST depression on the exercise electrocardiogram (6, 10 and 13, respectively, p less than 0.05). The left ventricular ejection fraction at rest and during peak exercise was similar among the 3 treatments. The therapeutic combination of nadolol and diltiazem is well tolerated and results in less evidence of myocardial ischemia during exercise than monotherapy with either agent.
Authors:
W E Miller; J Vittitoe; R A O'Rourke; M H Crawford
Related Documents :
3083664 - Metoprolol, nifedipine, and the combination in stable effort angina pectoris.
3929584 - Double-blind trial comparing labetalol with atenolol in the treatment of systemic hyper...
1674394 - Effects of a single oral administration of epanolol on exercise tolerance in patients w...
6419574 - Oral sustained-release nitroglycerin in chronic stable angina: a multicenter, double-bl...
23552344 - New insights into the aspects of pulmonary diffusing capacity in fontan patients.
606304 - Changes of p50 in hypoxaemia, hypercapnia and polycythaemia: multivariate analysis.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The American journal of cardiology     Volume:  62     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1988 Sep 
Date Detail:
Created Date:  1988-09-30     Completed Date:  1988-09-30     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  372-6     Citation Subset:  AIM; IM    
Affiliation:
University of Texas Health Science Center, San Antonio 78284-7872.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angina Pectoris / complications,  drug therapy*,  physiopathology
Blood Pressure
Coronary Disease / etiology,  prevention & control*
Diltiazem / adverse effects,  blood,  therapeutic use*
Electrocardiography
Female
Heart / physiopathology
Heart Rate
Heart Ventricles
Humans
Male
Middle Aged
Nadolol / adverse effects,  blood,  therapeutic use*
Physical Exertion*
Grant Support
ID/Acronym/Agency:
T32 HL07350/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
42200-33-9/Nadolol; 42399-41-7/Diltiazem

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Presentation and late outcome of myocardial infarction in the absence of angiographically significan...
Next Document:  Termination of tachycardias by interrupting blood flow to the arrhythmogenic area.